US EditionPublished • loading... • Updated
BioVersys Shareholders Approve All Board Proposals at Annual General Meeting
Summary by citybuzz.co
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
BioVersys Shareholders Approve All Board Proposals at Annual General Meeting
BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company focused on developing novel antibacterial treatments for multi-drug resistant (MDR) infections, announced today that all proposals by its Board of Directors were approved by shareholders at the Annual General Meeting (AGM). The company, based in Basel, Switzerland, is advancing its lead candidate BV100 into a global Phase 3 trial for Acinetobacter baumannii infections, a seriou…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
